We have just released our latest MID-Frail consortium newsletter with a round-up of all the project news – you can read it here [1]. The big story is that as of March 2015 we have 65 sites active and 500 subjects recruited.
The study executive committee has decided to institute an Intellectual Property Committee (IPC) for the MID-Frail study, like the one we have for the Frailomic project. The purpose of the IPC is to ensure consensus of all participating partners on the publications process, so that dissemination of our findings runs as smoothly as possible in the future. The IPC representatives will be expected to oversee and approve all MID-Frail-related publications (including abstracts, posters and oral presentations at conferences), ensuring that they do not infringe on patent applications.
The newsletter also reports on great advances in our publication strategy with a poster entitled ‘Evaluation of a therapeutic insole device on postural stability in older people with type 2 diabetes (SENSOLE feasibility study)’ being accepted for presentation at the International Academy Nutrition and Aging meeting in Barcelona, Spain in June.
This meeting will discuss various topics, with an underlying theme of preventing frailty and loss of function with advancing age. The proceedings will be published in the Journal of Nutrition Health & Aging. The Sensole sub-study is designed to analyse kinetic and kinematic movement data. In addition, a manuscript describing the conduct and results of the first part of the Sensole sub-study is being prepared. Keep reading the newsletters for further updates on this manuscript! More information can be found on the consortium website [2].
References
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
